Currently Viewing:
Cost-Sharing Roundtable — The Patient Assistance Safety Net: How Many Need Help? How Many Are Helped?
Currently Reading
Addressing Financial Concerns at the Outset to Improve Patient Outcomes
March 02, 2018
Michele McCourt Discusses Growing Financial Hardships for Patients With Cancer
March 03, 2018
M. Kristina Wharton on the Role of Federally Qualified Health Centers
March 04, 2018
Where Does the Existing Healthcare Safety Net Fall Short?
March 05, 2018
Cost-Sharing Roundtable—Introduction
March 05, 2018
Patient Education Vital for Improved Medicare Access, Say Panelists
March 06, 2018
Policy Improvement Areas to Reduce Financial Hardship
March 07, 2018
Dr Todd Yezefski Discusses Using Financial Navigator Programs
March 08, 2018
Ed Haislmaier on Policy Changes That Impact Healthcare Financial Burdens
March 09, 2018
Leigh Purvis Discusses the Burden of High Prescription Drug Costs
March 14, 2018
Ed Haislmaier: Impact of Business Coalitions on Healthcare Costs
March 23, 2018
Dan Klein on Lack of Cost Sharing in Medicare, Drugs Coming Down the Pipeline
March 27, 2018
Michele McCourt Discusses Impact of High Costs for Patients With Cancer
March 27, 2018
Kristina Wharton Analyzes the Health of the Population Using FQHCs
March 29, 2018
Dr Todd Yezefski Discusses the Financial Hardships of Cancer Treatment
March 30, 2018
Leigh Purvis on Out-of-Pocket Costs for Medicare Beneficiaries
March 31, 2018
Ed Haislmaier: Medicare Is "Stuck in a Time Warp"
April 04, 2018
Dan Klein Outlines Policy Changes to Strengthen the Safety Net
April 05, 2018
Kristina Wharton Discusses Services Provided at Federally Qualified Health Centers
April 09, 2018
Dr Todd Yezefski on the Benefits of Financial Navigators in Oncology
April 14, 2018
Ed Haislmaier on Efforts to Lower Drug Costs
April 15, 2018
Michele McCourt on Potential New Therapies for Patients With Cancer
April 17, 2018
Leigh Purvis Outlines the Burdens of High Drug Costs on Medicare Beneficiaries
April 20, 2018
Dan Klein Explains the Need for Patient Assistance Foundations
April 22, 2018

Paul Billings Discusses the Financial Burden of Prescription Drug Costs in Medicare

Unlike commercial plans, Medicare beneficiaries run the risk hitting the donut hole, which causes their costs to go up dramatically, said Paul Billings, senior vice president advocacy for the American Lung Association.


Unlike commercial plans, Medicare beneficiaries run the risk hitting the donut hole, which causes their costs to go up dramatically, said Paul Billings, senior vice president advocacy for the American Lung Association.

Transcript

How does the financial burden of high prescription drug costs among the Medicare population differ from the non-Medicare population?

So, Medicare’s prescription drug benefit is designed differently than many private health plans, and what we see is that patients hit what is known as the donut hole, where their costs go up dramatically through their plan year, and that leads to patients having to face much higher costs when they show up at the pharmacy counter.

We had an experience with a patient that was used to paying $42 for each prescription, and she showed up and it was $175. It was quite a shock to her and she couldn’t afford it. So, patients experience these high costs and all of a sudden it can impact their ability to afford medication, and if they can’t afford their medication, it can lead to a wide range of additional health burdens. People with chronic obstructive pulmonary disease can end up hospitalized when they’ve had an exacerbation, rather than maintaining good health or managing their disease by being able to adhere to their medications.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up